We are live on ! Find out more
UTHR icon

United Therapeutics

334 hedge funds and large institutions have $7.13B invested in United Therapeutics in 2014 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 93 increasing their positions, 147 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 36

5% more funds holding

Funds holding: 319334 (+15)

5% more capital invested

Capital invested by funds: $6.8B → $7.13B (+$336M)

4% more call options, than puts

Call options by funds: $39.2M | Put options by funds: $37.8M

28% less funds holding in top 10

Funds holding in top 10: 1813 (-5)

37% less repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 147

Holders
334
Holders Change
+15
Holders Change %
+4.7%
% of All Funds
8.91%
Holding in Top 10
13
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-27.78%
% of All Funds
0.35%
New
54
Increased
93
Reduced
147
Closed
36
Calls
$39.2M
Puts
$37.8M
Net Calls
+$1.37M
Net Calls Change
+$239M
Name Holding Trade Value Shares
Change
Change in
Stake
AllianceBernstein
126
AllianceBernstein
Tennessee
$4.73M +$361K +2,800 +8%
GIA
127
Gargoyle Investment Advisor
New Jersey
$4.71M
CIA
128
Capital Impact Advisors
Massachusetts
$4.71M
ERSOT
129
Employees Retirement System of Texas
Texas
$4.66M
KCM
130
Kingdon Capital Management
New York
$4.61M +$4.59M +35,600 New
ACPU
131
Arrowgrass Capital Partners (US)
Delaware
$4.53M +$1.93M +15,000 +75%
SAM
132
Shell Asset Management
Netherlands
$4.34M
SIM
133
Spark Investment Management
New York
$4.34M -$722K -5,600 -14%
AAM
134
Advisors Asset Management
Colorado
$4.2M -$244K -1,892 -6%
TCM
135
Tributary Capital Management
Nebraska
$4.14M -$1.55M -11,999 -27%
LG
136
Leuthold Group
Minnesota
$4.13M +$4.11M +31,862 New
SDIC
137
South Dakota Investment Council
South Dakota
$4.12M
CMBA
138
C.M. Bidwell & Associates
Hawaii
$3.97M -$5.8K -45 -0.1%
Barclays
139
Barclays
United Kingdom
$3.96M +$1.78M +13,827 +82%
MOACM
140
Mutual of America Capital Management
New York
$3.88M +$35.1K +272 +0.9%
GCP
141
GSA Capital Partners
United Kingdom
$3.83M +$1.25M +9,666 +49%
CS
142
Candriam SCA
Luxembourg
$3.75M +$3.74M +29,000 New
UBS AM
143
UBS AM
Illinois
$3.74M -$3.11M -24,147 -46%
QI
144
QS Investors
New York
$3.71M +$1.95M +15,166 +112%
Bank of America
145
Bank of America
North Carolina
$3.71M -$3.89M -30,219 -51%
ASRS
146
Arizona State Retirement System
Arizona
$3.64M -$155K -1,200 -4%
Capital Fund Management (CFM)
147
Capital Fund Management (CFM)
France
$3.58M +$3.56M +27,646 New
B
148
Baird
Wisconsin
$3.49M -$496K -3,850 -13%
SCM
149
Sterling Capital Management
North Carolina
$3.42M -$42.3K -328 -1%
DekaBank Deutsche Girozentrale
150
DekaBank Deutsche Girozentrale
Germany
$3.42M -$2.15M -16,662 -39%

UTHR Hedge Fund Activity: Q4 2014 in Review

334 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q4 2014, worth a combined $7.13B — up 4.9% from $6.8B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new UTHR positions and 36 closed out — a net gain of 18 holders — while 93 added to existing stakes and 147 trimmed.

The largest buyer was Scopia Capital Management, adding an estimated $41.6M. The largest seller was Herndon Capital Management, cutting an estimated $145M.

  • 334 institutional investors held United Therapeutics (UTHR) as of Q4 2014, up from 319 in Q3 2014.
  • Funds reported $7.13B of United Therapeutics stock for Q4 2014, up 4.9% quarter-over-quarter.
  • 54 funds opened new United Therapeutics positions in Q4 2014 and 36 closed out, a net change of +18 holders.
  • The largest United Therapeutics buyer in Q4 2014 was Scopia Capital Management, an estimated $41.6M added.
  • The largest United Therapeutics seller in Q4 2014 was Herndon Capital Management, an estimated $145M sold.

Based on aggregated 13F filings for Q4 2014.